Interesting study from #Finland with a "highly manufacturable and stable trimeric antibody-mimetic #sherpabody":
https://doi.org/10.1038/s41467-023-37290-6

From the abstract: "TriSb92 potently neutralizes #SARS-CoV-2, including the latest Omicron variants (...). In female Balb/c mice intranasal administration of just 5 or 50 micrograms of TriSb92 as early as 8 h before but also 4 h after SARS-CoV-2 challenge can protect from infection."

#Covid

#Intranasal trimeric #sherpabody inhibits #SARS-CoV-2 including recent immunoevasive #Omicron subvariants https://www.nature.com/articles/s41467-023-37290-6